Shingles Vaccine Market Report Scope & Overview
The shingles vaccine market is experiencing robust worldwide expansion driven by rising disease incidence, aging demographics, and accelerating national immunization strategies. Valued at USD 4.86 billion in 2024, the market is projected to reach USD 12.31 billion by 2032, advancing at a CAGR of 12.35% from 2025 to 2032. The continued rise in herpes zoster cases—especially among populations aged 50 and above—combined with strong government recommendations and reimbursement support, is reshaping global vaccination trends.
Global Shift Toward Preventive Care Fuels Market Momentum
A key driver of the growing shingles vaccine market is the rapid expansion of national immunization programs. The CDC estimates that 1 in 3 Americans will develop shingles during their lifetime, with over 1 million new cases annually. This rising burden has prompted countries across North America, Europe, and Asia Pacific to adopt shingles vaccines as part of their adult immunization schedules.
Access Key Market Insights: Request a Sample Report Now: https://www.snsinsider.com/sample-request/7051
The WHO has projected a dramatic rise in the global elderly population, which is expected to nearly double by 2050 and reach 2.1 billion individuals aged 60+. This aging demographic is significantly more vulnerable to shingles and its complications, creating an urgent need for widespread shingles vaccination access.
National Campaigns Strengthen Market Penetration
The shingles vaccine market is strongly influenced by government initiatives, policy support, and reimbursement reforms. Countries like the UK, Germany, and South Korea have integrated shingles vaccination into their national immunization programs, resulting in higher awareness and increased coverage.
The UK alone reported a 31.2% vaccination coverage rate for age 70 and 74.9% for age 76 during 2021–2022. Similarly, the U.S. has administered over 90 million doses of Shingrix since 2017, demonstrating strong commitment from both healthcare providers and policymakers toward shingles prevention.
Government backing remains a strong catalyst for the shingles vaccine market, especially as nations update adult vaccination frameworks to include recombinant vaccines like Shingrix.
Recombinant Vaccines Lead Due to High Efficacy and Safety Profile
The product landscape within the shingles vaccine market is dominated by Shingrix, which held 92% market share in 2024. Its recombinant, adjuvanted formulation provides more than 90% efficacy, making it the preferred choice for adults aged 50+ and immunocompromised individuals aged 18+.
Global health authorities including the CDC, WHO, and EMA recommend recombinant vaccines as the first-line preventive solution. Backed by long-term safety data and substantial government endorsements, recombinant shingles vaccines represent the strongest growth opportunity within the global shingles vaccine market.
Shingrix adoption is poised to rise further following GSK’s 2025 FDA review of its more convenient prefilled syringe format designed to simplify administration.
Meanwhile, SKYZoster is expanding rapidly—growing at 14.44% CAGR—especially across Asia Pacific due to affordability and government inclusion in national programs. The vaccine’s approvals in Malaysia and South Korea are further boosting its regional uptake.
Market Growth Supported by Increased Healthcare Spending and R&D Advancements
The U.S. government invested approximately USD 9 billion in vaccine R&D in 2023, accelerating advancements in recombinant technology and immunology. Increasing global concern for infectious diseases and the rising inclination toward preventive healthcare are factors amplifying the shingles vaccine market’s long-term growth.
Pipeline developments by major players—including Pfizer, BioNTech, Dynavax, GSK, and SK Bioscience—demonstrate a strong research focus on next-generation shingles vaccines. These include mRNA candidates, novel adjuvant systems, and improved delivery formats.
Regional Outlook: North America Maintains Lead While Asia Pacific Shows Fastest Growth
North America accounted for 61% of global market share in 2024, maintaining its dominance due to high disease prevalence, favorable reimbursement policies, and strong uptake of recombinant vaccines. The U.S. commanded 83% of North America’s share, valued at USD 2.57 billion in 2024, and is set to reach USD 6.45 billion by 2032.
Europe remains a lucrative region for the shingles vaccine market thanks to well-established vaccination systems. Countries like Germany, France, and the UK continue expanding adult vaccination programs, contributing to higher adoption rates.
Asia Pacific stands out as the fastest-growing region with a projected 13.33% CAGR. Japan, China, South Korea, and India represent high-potential markets due to aging populations and increased healthcare investments. Public awareness programs and increasing health expenditure further accelerate growth across Asia Pacific.
LAMEA (Latin America, Middle East, and Africa) remains in the developing stage but shows stable progress as governments emphasize preventive healthcare and work to improve vaccine accessibility.
Heightened Demand for Market Data: Our Full Report Provides Extensive Trend Analysis: https://www.snsinsider.com/reports/shingles-vaccine-market-7051
Key Companies Transforming the Shingles Vaccine Landscape
Major shingles vaccine market players include:
- GlaxoSmithKline (GSK)
- Merck & Co.
- Pfizer Inc.
- SK Bioscience
- BioNTech SE
- GeneOne Life Science
- Jiangsu Recbio Technology
- Vaccitech
- Curevo Inc.
These leaders continue to invest in R&D, global distribution networks, and strategic partnerships to enhance vaccine accessibility and long-term protection outcomes.
Recent Industry Developments Strengthening Market Expansion
- April 2024: GSK announced long-term data showing Shingrix provides protection for over 10 years among adults aged 50+.
- June 2024: Dynavax initiated Phase 1/2 trials for its new shingles vaccine candidate.
- February 2023: Pfizer and BioNTech launched Phase 1/2 testing for their mRNA-based shingles vaccine candidates.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
Frequently Asked Questions
- What is the projected market size of the shingles vaccine market by 2032?
The shingles vaccine market is expected to reach USD 12.31 billion by 2032.
- Which region dominated the shingles vaccine market in 2023?
North America held the largest share, contributing 61% of the global market.
- What is the CAGR of the shingles vaccine market?
The market is growing at a CAGR of 12.35% from 2025 to 2032.
- What are the key drivers of the shingles vaccine market?
Major drivers include rising shingles incidence, expanding immunization programs, aging populations, strong government policies, and high vaccine efficacy.
- Which product segment dominated the shingles vaccine market?
Shingrix led the market with 92% share, driven by superior efficacy and global regulatory endorsements.
